Medical College, Lincoln tlospital Center, Department of Pediatrics, Bronx, NY 42 children with asthma who had been taking aerosol medication from canister nebulizers for longer than 6 months were evaluated for aerosol inhalation technique. Proper inhalation technique is a simple procedure. Patient should close lips around the mouthpiece of the nebulizer and exhale first. As the canister is actuated he should inhale deeply by mouth and breathhold for a few seconds before exhaling. The mouthpiece of a canister nebulizer was modified so that actuation of the canister and inhalation through the mouthpiece could be recorded on paper. The age range of the patients was 7 to 15. They were either on bronchodilator or steroid aerosols or a combination of both. Of the 42 tested, 24 had correct technique and 18 (43%) did not. 11 simply squirted the aerosol into the mouth without inhaling. 6 lnhaled first, then actuated the aerosol. One inhaled only a whiff of air (501111) apnea. The site of obstruction was iocalized by fl"orosco&-t& son, but 1 could nit be taught even after 6 lessons. Incorrect the hypopharynx in 618 of cases studied The abnormalities seen inhalation technique is a frequent finding among asthmatics takin group 1 were reversed by simple T&A.'~rou~ 2 required more complex surgical~procedures. We feel children presenting as moding aerosol medications. The physician starting this form of therately severe SD should be evaluated with teats of nirwav frmr-
er&y should be certain to teach each patient the correct inhaltion and airway fluoroscopy prior to-and-after surgery. -. atibi technique and also check those already on it.
ORAL VERSUS AEROSOL ADRENERGIC BRONCHODILATORS IN AS-TNMA Haesoon Lee (Spon. by Lawrence R. Shapiro).New 1683 York ~edic-eEe, Lincoln Hospital Center, Department of Pediatrics, Bronx, NY 17 children attending asthma clinic who had moderate airways obstruction and who were in clinically stable condition were tested for bronchodilator response to aerosol and oral adrenergic agonists in a double blind randomized sequence on 4 different days. 4 regimens were: Aerosol-metaproterenol aerosol (Alupent) 1 puff (0.65mg) at the start and at 20 and 40 minutes plus placebo tablets, Oral-metaproterenol tablets 10-20mg or terbutaline 2.5-5mg by mouth based on weight plus placebo aerosols, Combineda combination of both actives, and Placebo-placebo tablets and aerosols. Forced vital capacity and forced expiratory volume in 1 second (FEV ) were measured before and after the therapy at 20, 40, 60, 120, 180, and 240 minutes. Side effects, blood pressure, and pulse rates were checked before and after the therapy. Oral therapy produced a slow improvement in FEVl which reached the maximum (26% above the baseline) at 120 minutes and started to decline.at 240 minutes. Aerosol therapy produced a prompt, marked increase in FEVl at 20 minutes which reached the maximum (39 %) at 120 minutes and started to decline at 180 minutes. FEVl response on the aerosol therapy was significantly greater than on oral therapy from 20 to 120 minutes. The combined therapy produced a slightly, but not significantly, greater response than the aerosol therapy throughout the test period. Side effects were frequent on the oral and combined therapy and infrequent on the aerosol regimen. Aerosol route is superior overall. Our previous studies (Lemen, et al. Am.Rev.Resp.Dis., 117:639-46, 1978) reported abnormal plasma PG concentrations in CF patients; but, the physiologic significance of these observations is unknown. We correlated plasma PGs to ADP induced platelet aggregation (PA) in 8 normal and 11 CF subjects. Platelet proaggregators (e.g. thromboxane (Tx)A2 as TxB2 and PGE2) and antiaggregators (PGI2 as 6-keto-Fk) were measured by radioimmunoassay. With parallelism between standards and plasma and with the withinsample coefficient of variation <9%, 6-keto-Fla was significantly (p '0.05) reduced in-CF patients (%SE 408 i 105 pg/ml) compared to normal subjects (X* SE 708 + 196 pg/ql). PGFza was significantly (p <0.05) elevated in CF patients (XiSE, 282 + 106 pg/ml compared to normal subjects (E~sE, 173 i 65). TxB2 and PGE2 were not different in CF patients (%+sE, 327 i 84 and 193 i 239 pglml, respectively) compared to normal subjects (XtSE, 318 i 92 and 995 * 495 pg/ml, respectively). ADP induced PA was inhibited in 13/18 studies in CF patients. Platelet electronmicrographs showed decreased dense bodieslplatelet profile in 418 studies, and PA correlated with dense bodies in 418 studies. PA was not correlated with drug therapy including antibiotics or vitamin E. We conclude that abnormal PG metabolism may result in abnormal platelet function in CF patients. Supported in part by grant HL 23773 and the Cystic Fibrosis Foundation. The increased occurrence o f pulmonary i n t e r s t i t i a l emphysema, pneumothorax, pneumomedi a s t i num, and pneumopericardi urn during mechanical v e n t i l a t i o n i s well known. However, the mechanical relationships during v e n t i l a t i o n between time, pressure and neonatal a i r l e a k syndrome (NAS) are poorly understood. 13 o f 56 i nfants (23%) v e n t i l a t e d w i t h pressure-cycled v e n t i l a t o r s (Bournes BP200 set t o d e l i v e r a square r e s p i r a t o r y wave form) developed roentgenographic findings o f NAS. 13 s i m i l a r l y v e n t i l a t e d i nfants (controls) who d i d n o t develop NAS were matched w i t h the NAS patients f o r b i r t h weight (Y=1485), gestational age (TT.31 wk), i n i t i a l mea; airway pressure (m) and i n i t i a l alveolar-to-arteria1 gradient (A-aDO ) Infants who developed NAS had p o s i t i v e changes i n PaFi. (+A&) u n t i l 60 h r o f l i f e , while controls showed -A P Z i a f t e r 12 h r o f l i f e . The APm f o r NAS patients i n the f i r s t 24 h r of l i f e was +3.5 cm H 0 vs -0.4 cm H 0 f o r cont r o l s (t=2.76, p<0.02). Average Pi l FT ?' or 108 h r was 6 . 9 cm H20 + 1.0 SEM f o r a i r l e a k i n f a n t s vs 8.3 cm Hz0 (t=3.0, p<0.01). We conclude: 1) i n f a n t s who develop NAS while undergoing pressurecycled v e n t i l a t i o n receive s i g n i f i c a n t l y higher Paw than i n f a n t s without NAS, and 2) the increase i n Paw during the f i r s t 24 h r o f v e n t i l a t i o n i s more r a p i d i n i n f a n t s who develop NAS; therefore, we a n t i c i p a t e an a i r l e a k i f the P m m u s t be increased more than 3.5 cm Hz0 i n f i r s t day o f mechanical v e n t i l a t i o n . In 6 BPD (3 to 43 m) measurements of intraesophageal pressure, airflow and tidal volume allowed calculations of total pulmonary resistance (RL) and dynamic compliance (CL). On distinct days for each drug, changes of RL and CL with diuretic,Furosemide (lmglkg IV), inhaled bronchodilators, Isoproterenol (1:200,.2cc) Atropine (.05mg/kg) were assessed. Each patient was his own control on the following "placebo" day. A two-tailed paired test was used to compare baseline values prior drug study, versus baseline values the following "control" day. The same T test was used to compare change of RL, CL in each group (Furo.,Isop.,Atr.) versus change during control day. Baseline values (n=26) revealed: On 23 instances, RL was between 150% and 450% of the predicted value; CL was below 75% of the predicted value in 5 instances. There was no significant difference in baseline parameters (p).05) prior drug study versus control day. Diuretic improved CL (p=.Ol,n=6), sympathomimetic improved RL (p=.07,n=5), parasympatholytic improved CL (p=.06,n=4). The study indicated that BPD had marked alteration in large airway (law) mechanism (RL). Small airway (Saw) function (CL) appeared normal in 13 instances, pointing out that only specific CL per liter of lung volume will assess Saw; however, changes of CL reflected Saw changes. PE and Law bronchospasm appeared coexisting factors in BPD. PE may also contribute to Saw (CL) through a vagal reflex.
